Novartis Ag (NVS) Income from Non-Controlling Interests (2009 - 2026)
Novartis Ag's (NVS) quarterly Income from Non-Controlling Interests came in at -$7.0 million in Q2 2026, up 58.82% year-over-year from -$4.4 million in Q2 2025, and up 50.0% quarter-over-quarter from -$14.0 million in Q4 2025.
Analysis
Novartis Ag (NVS) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends
Novartis Ag has disclosed Income from Non-Controlling Interests across 18 years of filings, most recently posting -$7.0 million for Q2 2026.
- In Q2 2026, Income from Non-Controlling Interests rose 58.82% year-over-year to -$7.0 million; the TTM figure through Jun 2026 stood at -$19.0 million (down 18.75% YoY), while the FY2025 annual figure was -$17.0 million, down 750.0% from the prior year.
- Income from Non-Controlling Interests came in at -$7.0 million for Q2 2026 at Novartis Ag, up from -$14.0 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $3.0 million in Q1 2025 to a low of -$17.0 million in Q2 2025.
- Average Income from Non-Controlling Interests over 5 years is -$2.1 million, with a median of $1.0 million recorded in 2022.
- Year-over-year, Income from Non-Controlling Interests soared 200.0% in 2022 and slumped 800.0% in 2025.
- Over 5 years, Income from Non-Controlling Interests stood at -$2.0 million in 2022, then soared by 200.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then tumbled by 800.0% to -$14.0 million in 2025, then surged by 50.0% to -$7.0 million in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$7.0 million in Q2 2026, -$14.0 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 10.00 Mn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -1.00 Mn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 39.52 Mn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.00 Mn |
| Dec 31, 2025 | -14.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | -17.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Sep 30, 2024 | -4.00 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2023 | 2.00 Mn |
| Jun 30, 2023 | 1.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | -2.00 Mn |
| Sep 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 1.00 Mn |
| Mar 31, 2022 | -3.00 Mn |
| Dec 31, 2021 | -2.00 Mn |
| Jun 30, 2021 | -1.00 Mn |
| Dec 31, 2020 | 5.00 Mn |
| Sep 30, 2020 | -3.00 Mn |
| Mar 31, 2020 | -3.00 Mn |